• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by argenx SE (Amendment)

    2/1/23 4:54:05 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email
    SC 13G/A 1 nl0010832176_020123.txt nl0010832176_020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ARGENX SE -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BWNH4H6 -------------------------------------------------------- (SEDOL Number) December 31, 2022 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BWNH4H6 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 3208899 (6) Shared voting power 0 (7) Sole dispositive power 3445779 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 3445779 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 6.2% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- ARGENX SE Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- Laarderhoogtweg 25 Amsterdam Netherlands 1101 EB Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 55 East 52nd Street New York, NY 10055 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) SEDOL No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 3445779 Percent of class 6.2% Number of shares as to which such person has: Sole power to vote or to direct the vote 3208899 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 3445779 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ARGENX SE. No one person's interest in the common stock of ARGENX SE is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 1, 2023 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Life Limited BlackRock International Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. iShares (DE) I Investmentaktiengesellschaft mit Teilgesellsc BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Asset Management Deutschland AG BlackRock (Luxembourg) S.A. BlackRock Investment Management (Australia) Limited BlackRock Advisors (UK) Limited BlackRock Fund Advisors BlackRock Asset Management North Asia Limited BlackRock (Singapore) Limited BlackRock Fund Managers Ltd *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BLACKROCK, INC., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Christopher Meade, Daniel Waltcher, Una Neary, Richard Cundiff, Charles Park, Enda McMahon, Arlene Klein, Con Tzatzakis, Karen Clark, David Maryles, Daniel Ronnen, John Stelley, Daniel Riemer, Elizabeth Kogut, Maureen Gleeson, Daniel Kalish and Spencer Fleming acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, is acting certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, Including without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any amendments to any of the Foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 8th day of December, 2015 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 2nd day of January, 2019. BLACKROCK, INC. By:_ /s/ Daniel Waltcher Name: Daniel Waltcher Title: Deputy General Counsel
    Get the next $ARGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    3/17/2025Mkt Perform → Outperform
    Bernstein
    3/12/2025Sell → Hold
    Deutsche Bank
    1/17/2025Hold → Sell
    Deutsche Bank
    11/12/2024$697.00Peer Perform → Outperform
    Wolfe Research
    11/5/2024$715.00Sector Perform → Sector Outperform
    Scotiabank
    11/1/2024$515.00 → $650.00Outperform → Neutral
    Robert W. Baird
    11/1/2024Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ARGX
    Leadership Updates

    Live Leadership Updates

    See more
    • argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

      January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

      1/16/23 1:30:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Ana Cespedes to Board of Directors

      December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

      12/12/22 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Camilla Sylvest to Board of Directors

      September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg

      9/8/22 2:10:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/14/24 1:22:37 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/12/24 9:50:11 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by argenx SE (Amendment)

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      2/14/24 10:03:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • argenx upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00

      5/13/25 8:50:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Bernstein

      Bernstein upgraded argenx from Mkt Perform to Outperform

      3/17/25 7:23:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Deutsche Bank

      Deutsche Bank upgraded argenx from Sell to Hold

      3/12/25 7:20:57 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Financials

    Live finance-specific insights

    See more
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      May 1, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium           32 800 50 201France          

      5/1/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

      $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering f

      2/27/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    SEC Filings

    See more

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      5/28/25 4:37:40 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      5/8/25 6:39:56 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      4/28/25 8:06:51 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      June 3, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company comm

      6/3/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Announces Results of Annual General Meeting of Shareholders

      May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company's share capital was represented at the Annual General Meeting. All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required. As part of the approved resolutions: The Company's 2024 remuneration report received a 76.7% majo

      5/28/25 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care